Overview

Lung Deposition of Beclometasone Dipropionate/Formoterol Fumarate/Glycopyrronium Bromide Administered Via pMDI in Healthy, Asthmatic and COPD Patients

Status:
Completed

Trial end date:
2017-04-11

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the lung deposition and distribution pattern of Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium Bromide using a Gamma-scintigraphic technique after inhalation of a single dose of 99mTc radiolabelled CHF 5993 Administered via pMDI in healthy volunteers, asthmatic and COPD patients.

Phase:

Phase 1

Details

Lead Sponsor:

Chiesi Farmaceutici S.p.A.

Treatments:

Beclomethasone
Bromides
Formoterol Fumarate
Glycopyrrolate